Highlighted Stocks: China Mobile Limited (NYSE:CHL), Sun Bancorp (NASDAQ:SNBC), Unisys Corporation (NYSE:UIS), BioDelivery Sciences International (NASDAQ:BDSI), Halozyme Therapeutics (NASDAQ:HALO)

China Mobile Limited (NYSE:CHL) shares moved up 4.46% in last trading session and ended the day at $59.45. CHL Gross Margin is 81.60% and its has a return on assets of 17.80%. China Mobile Limited (NYSE:CHL) quarterly performance is -6.47%.

China Mobile Limited is an investment holding company. The Company is engaged in providing mobile telecommunications and related services in 31 provinces, autonomous regions and directly-administered municipalities in Mainland China and Hong Kong Special Administrative Region through its subsidiaries.

China Mobile (NYSE:CHL) had its target price lowered by Jefferies Group from $76.70 to $76.13 in a report issued on Monday morning, StockTargetPrices.com reports. The brokerage currently has a buy rating on the stock.

Sun Bancorp Inc. (NASDAQ:SNBC) ended the last trading day at $19.69. Company weekly volatility is calculated as 2.61% and price to cash ratio as 1.25. Sun Bancorp Inc. (NASDAQ:SNBC) showed a weekly performance of -0.86%.

Sun Bancorp, Inc. is a bank holding company. The Company’s principal subsidiary is Sun National Bank (the Bank). Through the Bank, the Company provides an array of community banking services to consumers, small businesses and mid-size companies. The Company’s lending services to businesses include term loans, lines of credit and commercial mortgages. The Company’s commercial deposit services include business checking and money market accounts and cash management solutions such as online banking, electronic bill payment and wire transfer services, lockbox services, remote deposit and controlled disbursement services.

On 31st August, Sun Bancorp, Inc. (NASDAQ:SNBC) reported that the Bank has completed the sale of its Hammonton, N.J. location along with related deposits and certain loans in Atlantic County to Cape Bank, the banking subsidiary of Cape Bancorp, Inc. (NASDAQ: CBNJ). The agreement of sale for this transaction was first announced in March 2015. The sale of the Bank’s Hammonton location included approximately $32.8 million in combined total deposits and approximately $354 thousand in fixed assets. In addition, approximately $4.8 million in combined local branch loans were sold at book value.

On 08 September, Unisys Corporation (NYSE:UIS) shares moved up 1.92% and was closed at $13.26. UIS EPS growth in last 5 year was -27.10%. Unisys Corporation (NYSE:UIS) year to date (YTD) performance is -55.02%.

Unisys Corporation is a global Information Technology (IT) company. The Company provides outsourcing and managed services, systems integration and consulting services, server technology, cybersecurity and cloud management software and maintenance and infrastructure support services.

On 4 September, it was reported Unisys Corporation’s (NYSE:UIS) Belgian subsidiary has successfully expanded the capabilities and performance of the check-in desks at Rotterdam The Hague airport (RTM) with its Fast Bag Drop Application, part of the Unisys Airport Passenger Processing System (APPS). Almost a quarter of the world’s air passengers now check into their flights using Unisys’ airline and airport systems.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) shares moved up 4.55% in last trading session and ended the day at $6.66. BDSI Gross Margin is 62.00% and its has a return on assets of -78.60%. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) quarterly performance is -19.66%.

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products and certain of its product candidates utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek).

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced that the Company will participate at Wells Fargo Securities Healthcare Conference and FBR Second Annual Healthcare Conference on 9 September, 2015.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) caters to the Healthcare space. It has a net profit margin of -35.20% and weekly performance is 0.69%. On the last day of trading company shares ended up $17.58. Halozyme Therapeutics, Inc. (NASDAQ:HALO) distance from 50-day simple moving average (SMA50) is -16.90%.

Halozyme Therapeutics, Inc. is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Company’s development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA).

On 24 August, Halozyme Therapeutics, Inc. (NASDAQ:HALO), named Michael J. LaBarre, Ph.D. as chief scientific officer, succeeding Dr. Michael Shepard, who was appointed a Research Fellow for the company. The move broadens Dr. LaBarre’s responsibilities to include research and development of early pipeline assets, in addition to his role managing product development and ENHANZE™ platform partnerships.